Misuse of over-the-counter medicinal formulations for intoxication reflects gaps in India's pharmaceutical regulatory architecture. Critically analyse.

Q. Misuse of over-the-counter medicinal formulations for intoxication reflects gaps in India's pharmaceutical regulatory architecture. Critically analyse. (15 marks, 250-350 words)

Medicinal tinctures of cardamom and ginger carrying up to 80–90% v/v ethyl alcohol were, until recently, sold without licence under Schedule K of the Drugs Rules, 1945 [2]. Their diversion for intoxication exposes real design gaps in India's drug regulation — though the recent corrective response shows the architecture is also self-correcting.

Gaps the misuse exposes - Exemption-based drafting: Schedule K exempted whole product categories from Chapter IV licensing, creating a legal channel for high-alcohol preparations to bypass pharmacy controls [1][2]. - Reactive, not anticipatory: the loophole closed only after State governments referred cases of misuse to the Centre, indicating weak surveillance of consumption patterns [2]. - Federal implementation deficit: drugs being a shared subject, enforcement rests with State Drug Control Authorities, whose capacity varies widely; central rule-making alone cannot ensure compliance. - Classification lag: Schedule H1, created in 2013 for habit-forming drugs, antibiotics and anti-TB medicines [3], was not extended to alcohol-based formulations for over a decade despite comparable abuse potential.

Countervailing strengths - The Drugs and Cosmetics Act, 1940 permits Schedule amendment through delegated legislation, allowing swift correction without fresh parliamentary law [1]. - A statutory technical filter exists: the DTAB examined and recommended the reclassification before notification [4]. - The 2026 amendment removes the Schedule K exemption for formulations above 12% v/v alcohol in packs exceeding 30 ml, shifting them to Schedule H1 with prescription-only sale and separate registers [1][2] — a proportionate step that curbs diversion while preserving therapeutic access [1].

The episode therefore reflects less an absent framework than a slow-moving one: India's drug law is legally equipped but institutionally reactive. Strengthening real-time pharmacovigilance, digitising Schedule H1 sale registers, and periodic DTAB review of exempted categories would convert episodic correction into continuous oversight — advancing the right to health read into Article 21 and the SDG-3 goal of substance-abuse prevention.

(~315 words)

Sources: 1. PIB, "Government amends Drugs Rules, 1945 to Strengthen Regulation of High Alcohol-Containing Drug Formulations" (July 2026) — Schedule K exemption removed, shift to Schedule H1, prescription-only sale, curbing diversion while retaining therapeutic availability 2. The Hindu, "Govt. amends rules to regulate drugs containing alcohol" (11 July 2026) — 80–90% v/v alcohol in tinctures, >12% v/v and >30 ml threshold, references from State governments 3. CDSCO, Inclusion of Schedule H1 (GSR 588(E), 30 August 2013) — origin and scope of Schedule H1; record-keeping obligations 4. CDSCO, Minutes of the 90th Drugs Technical Advisory Board meeting (2024) — DTAB recommendation preceding the reclassification